key: cord-0939635-cdnpmps2
authors: Macauley, Precious; Epelbaum, Oleg
title: Epidemiology and Mycology of Candidaemia in non‐oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non‐COVID‐19 and COVID‐19 cases
date: 2021-03-08
journal: Mycoses
DOI: 10.1111/myc.13258
sha: cc5cc3dc4ae65379dccc543a897ba05181ac86fd
doc_id: 939635
cord_uid: cdnpmps2

The epidemiology and mycology of invasive candidiasis in the ICU is well‐described in certain types of critically ill patients but not in others. One population that has been scarcely studied is non‐neutropenic patients admitted specifically to medical ICUs. Even less is known about the broader category of medical ICU patients without active oncological disease. This group constitutes a very large share of the patients requiring critical care across the globe, especially in the era of the SARS‐CoV‐2 pandemic. We analysed medical ICU candidaemia episodes that occurred in non‐oncological patients in our tertiary academic centre in the United States from May 2014 to October 2020 to determine the incidence and species distribution of the associated isolates. We then separately considered non‐COVID‐19 and COVID‐19 cases and compared their characteristics. In the non‐COVID‐19 group, there were 38 cases for an incidence of 1.1% and rate of 11/1000 admissions. In the COVID‐19 group, there were 12 cases for an incidence of 5.1% and rate of 51/1000 admissions. In the entire sample, as well as separately in the non‐COVID‐19 and COVID‐19 groups,Candida albicans accounted for a minority of isolates. Compared to non‐COVID‐19 patients with candidaemia, COVID‐19 patients had lower ICU admission SOFA score but longer ICU length of stay and central venous catheter dwell time at candidaemia detection. This study provides valuable insight into the incidence and species distribution of candidaemia cases occurring in non‐oncological critically ill patients and identifies informative differences between non‐COVID‐19 and COVID‐19 patients.

Invasive mycosis caused by Candida species, most commonly detected clinically as candidaemia, is a major form of nosocomial infection particularly prevalent in intensive care units (ICUs). Historically, invasive candidiasis (IC) has been associated most closely with two categories of ICU cases: Oncological patients with neutropenia and surgical patients with abdominal pathology. While the importance of Candida as a pathogen in non-neutropenic medical ICU patients has been increasingly recognised, studies restricted to this fundamental ICU population remain few. Among the features of IC rarely studied in this specific population is the relative distribution of albicans versus non-albicans species among contemporary isolates, an issue of importance because some studies in undifferentiated ICU populations have suggested a shift from the traditional majority of the former to a majority of the latter. [1] [2] [3] The ongoing pandemic of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which has created a global explosion in the number of critically ill patients with respiratory failure, has contributed an additional question: Has the pandemic changed the incidence, patient characteristics, and speciation of IC cases in medical ICUs? We performed the present analysis of our medical ICU non-oncological candidaemia cases in order to describe the epidemiology and mycology of IC in this population as well as to compare those with and without coronavirus disease 2019 (COVID).

All patients older than 18 years of age belonging to the medical ICU service at Westchester Medical Center (WMC), a tertiary university hospital in Valhalla, NY, between 1 May 2014 and 31 October 2020 whose blood cultures drawn at any time following admission to the ICU yielded Candida species were potentially eligible for inclusion in this study. These cases were identified through a query of the pathogen database maintained by the WMC Department of Microbiology.

In WMC, identification and speciation of fungal isolates are performed using the Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Biotyper CA system (BRUKER Corp.). Patients with severe neutropenia (absolute neutrophil count < 500 cells/ µl) at the time of index ICU admission and also active recipients of chemotherapy for an oncological diagnosis at the time of the index hospitalisation were excluded. Patients eligible for analysis after the application of these inclusion and exclusion criteria were then screened for positivity for SARS-CoV-2 by polymerase chain reaction testing of a nasopharyngeal swab specimen. Those who were found to be positive for SARS-CoV-2 formed the COVID group, within the study; all others comprised the non-COVID group. Demographic, clinical and mycological characteristics of the study patients were extracted retrospectively from the institutional electronic medical record. The date of the first positive fungal blood culture was used for calculation of all durations. Receipt of antibacterial therapy was counted only if the last dose had been administered within 30 days prior to the acquisition of the blood culture. Patients were considered corticosteroid recipients if they had been exposed to these agents at any dose within 3 days of the blood culture. Central venous catheter (CVC) dwell time in days was calculated from the date of insertion (day 0) to the date of the blood culture. If the insertion date was not available (eg, for patients transferred from outlying hospitals), the date of medical ICU entry was taken as day 1 of CVC dwell. In case of the presence of more than one CVC at the time of positive blood culture, the CVC with the longest dwell time was the one counted.

Patients designated as recipients of new renal replacement therapy (RRT) were those started on RRT during the index hospitalisation and prior to the date of the positive blood culture. Patients designated as having end-stage renal disease (ESRD) were recipients of ambulatory RRT prior to hospitalisation. The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to and the appropriate ethical review committee approval has been received. The institutional review board of New York Medical College approved this study (protocol #14091).

All categorical variables are expressed as frequencies and percentages. Comparisons of categorical variables were performed using Fisher's Exact Test. Continuous variables are expressed as median (IQR) unless otherwise specified, in which case they are expressed as mean ± SD. The Mann-Whitney U Test was used for statistical inference on non-normally distributed data while the two-tailed Student's T test was used for statistical inference on data not expected to violate normality. P-value of < 0.05 was taken to be statistically significant. Microsoft Excel 2016 supplemented by a calculator application publically available at www.stats kingd om.com was used for the statistical analysis.

During the 78-month span of the study period, there were 3,568 non-COVID adults and 236 COVID adults admitted to the medical ICU service at WMC. After the application of our exclusion criteria, a total of 50 unique patients with candidaemia were identified for an overall incidence of 1.3% and a corresponding incidence rate of 13/1000 admissions. There were 38 candidaemic patients in the non-COVID group and 12 in the COVID group. These numbers translated into an incidence of 1.1% in the non-COVID group and 5.1% in the COVID group. The corresponding incidence rates were 11/1000 admissions in the non-COVID group and 51/1000 admissions in the COVID group. The demographic and clinical characteristics of the study population are summarised in Table 1 , which also compares the non-COVID and COVID groups. There were no statistically significant differences between the two groups with respect to demographic features, frequency of any of the tabulated risk factors for IC or pre-candidaemia corticosteroid exposure. There was a statistically significant difference in the sequential organ failure assessment (SOFA) score on admission to the ICU, which was higher in the non-COVID group (10, IQR 8-12 vs. 5, IQR 4-9; P =.006) indicating a greater burden of organ dysfunction in those patients.

On the other hand, the ICU length of stay prior to development of candidaemia was significantly longer in the COVID group (19 days, IQR 11-28 vs. 5 days, IQR 2-9; P =.001) as was the CVC dwell time (12.5 days, IQR 7-19 vs. 5.5 days, IQR 2-9; P =.022). There was no significant difference in crude hospital mortality between the two groups. The Candida species distribution in the overall population as well as separately in the non-COVID and COVID groups is presented in Table 2 Other non-C.albicans Conversely, an Australian study restricted to non-neutropenic ICU patients reported a mean incidence rate of 2.06/1000 admissions, but approximately 68% of the population had undergone recent surgery. 5 Contrary to precedent, we elected to limit our study population to not just those without neutropenia but also to those without actively treated malignancy. This was done to investigate a population that is largely unexplored in IC research yet one that constitutes the core of the pathology treated in general medical ICUs across the globe. Another reason for this decision was that even those onco- Table 3 . 6,10-19 As in our study, a non-albicans majority has been observed among COVID candidaemia isolates in another tertiary academic centre in the United States, 18 whereas an albicans majority was recorded across three Brazilian tertiary hospitals 17, 19 as well as in the United Kingdom 16 and Italy. 6 Unlike our study of exclusively ICU patients, not all of these comparator studies of COVID candidaemia were limited to patients cared for in an ICU setting.

The third major contribution of this study is the comparison between candidaemic ICU patients without COVID and those with COVID in our institution. We detected a nearly 5-fold greater incidence of ICU candidaemia among COVID patients as compared to non-COVID patients. Such an increase is consistent with other early reports of comparative incidence available at the time of this writing (Table 3) We also compared CVC dwell time, and found it to be significantly longer in the COVID group. This was an expected finding given the naturally higher threshold for CVC manipulations at the height of the pandemic from a staff exposure perspective. Taken together, the longer ICU stay and CVC dwell time prior to detection of IC that differentiate our COVID group from the non-COVID group suggest that the increased candidaemia incidence rates emerging in reports such as ours may stem from the prolonged stays and extended CVC days that appear to characterise the ICU course of these patients.

The precise impact of length of ICU stay, CVC dwell time, and intensity of corticosteroid exposure on the development of candidaemia in critically ill patients with COVID remains in need of further elucidation as these patients may differ from traditional medical ICU patients with respect to these parameters. The high crude hospital mortality rate of non-COVID candidaemic patients (61%) and ones with COVID (75%) is comparable with reports from both within 6, 17, 19 and outside 20-22 the pandemic era.

Our study suffers from a number of limitations, primary among them its retrospective nature and the interrelated problems of single-centre design and relatively small sample size. We made the unconventional decision to exclude not only neutropenic patients, which is typical but also active oncological patients, the rationale for this decision having been discussed earlier. The justification for the latter exclusion is debatable. Additionally, we compared COVID patients whose admissions were limited to a 5-month-period in 2020

to non-COVID patients some of whose admissions dated to as far back as 2014. As a result, evolution in ICU management approaches over the span of the study may have influenced the comparison.

Finally, we reported corticosteroid exposure as a binary variable rather than calculating the cumulative corticosteroid dosing, which may have masked the impact of intensity of corticosteroid therapy.

This single-centre retrospective study from an academic tertiary referral centre in the United States provides an estimate of the incidence of IC as measured by candidaemia in a population of nonneutropenic, non-oncological medical ICU patients. Furthermore, this study adds the United States to the shortlist of countries whose

ICUs have reported non-albicans Candida together comprising the majority of candidaemia isolates. Finally, we add to the small but growing body of literature comparing non-COVID ICU candidaemia patients to those with COVID; we observed a lower ICU admission SOFA score in the COVID group, indicating a tendency of these patients to enter the ICU with dysfunction of fewer organs; we also found a greater ICU length of stay prior to the development of candidaemia in the COVID group, suggesting that it is a more delayed phenomenon in the course of critical illness in these patients. The longer CVC dwell duration at time of candidaemia in the COVID group of our study merits consideration as one of the reasons for the recent increase in the incidence of this infection in the ICU brought about by the impact of the SARS-CoV-2 pandemic on vascular catheter management.

None.

The authors have no conflicts of interest to disclose. 

Incidence, characteristics and outcome of ICU-acquired candidemia in India

Epidemiology of Candida isolates from Intensive Care Units in Colombia from 2010 to

Candidemia in a public hospital in Northeastern Brazil: epidemiological features and risk factors in critically ill patients

CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome

Determinants of mortality in non-neutropenic ICU patients with candidaemia

Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls

Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units

Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units

Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis

Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: an alarming "collateral effect

Bloodstream infections in critically ill patients with COVID-19

Unexpectedly high frequency of enterococcal bloodstream infections in coronavirus disease 2019 patients admitted to an Italian ICU: an observational study

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

COVID-19 associated invasive candidiasis

Multidrug-resistant candida auris infections in critically ill coronavirus disease patients

A National strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Is the frequency of candidemia increasing in covid-19 patients receiving corticosteroids?

Fungemia in covid -19 ICU patients, a single medical center experience

Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic

Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France

Worrisome trends in incidence and mortality of candidemia in intensive care units

Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period

How to cite this article: Macauley P, Epelbaum O. the United States: overall analysis and comparison between non-COVID-19 and COVID-19 cases